

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業

Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**PROPOSED AMENDMENT TO THE MEMORANDUM AND
ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND
RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION**

Pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), Mabpharm Limited (the “**Company**”) announces that the board of directors of the Company (the “**Board**”) proposes to amend the existing memorandum and articles of association of the Company (the “**M&A**”) for the purpose of (i) aligning the M&A with the most recent legal and regulatory requirements under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the Listing Rules, which allow the Company to hold treasury shares (with the meaning ascribed to it under the Listing Rules) for potential future resale or transfer under specified conditions; (ii) providing more flexibility to the Company in relation to the conduct of general meetings (including hybrid or fully electronic meetings); (iii) bringing the M&A in line with the expanded paperless listing regime and electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules; and (iv) implementing consequential and other necessary housekeeping amendments to the M&A in accordance with the requirements of the Listing Rules and the laws of the Cayman Islands (the “**Proposed Amendments**”).

Pursuant to the M&A and the relevant laws and regulations, the Proposed Amendments and the adoption of the amended and restated memorandum and articles of association (the “**Amended M&A**”) incorporating such amendments are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at general meeting of the Company. A special resolution to consider and approve the Proposed Amendments and the adoption of the Amended M&A incorporating such amendments will be proposed at the forthcoming annual general meeting of the Company (the “**AGM**”). A circular containing, among others, the details of the Proposed Amendments and the adoption of the Amended M&A, together with a notice of the AGM, will be published and sent to the Shareholders in due course in accordance with the Listing Rules.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, March 26, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.